Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

Published:2017-11 Issue: Volume:30 Page:44-49
ISSN:1567-5688
Container-title:Atherosclerosis Supplements
language:en
Short-container-title:Atherosclerosis Supplements

Author:

Schettler V.J.J.,Ringel J.,Jacob S.,Julius U.,Klingel R.,Heigl F.,Roeseler E.,Grützmacher P.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Reference42 articles.

1. Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from ATVB council;Hegele;Arterioscler Thromb Vasc Biol,2015

2. Shared and non-shared familial susceptibility of coronary heart disease, ischemic stroke, peripheral artery disease and aortic disease;Calling;Int J Cardiol,2013

3. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials;Fulcher;Lancet,2015

4. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT;Bohula;Circulation,2015

5. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011;Ray;Eur Heart J,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Historical Profiling of Dry Eye Patients – Potential Trigger Factors and Comorbidities;Klinische Monatsblätter für Augenheilkunde;2022-12-29

2. Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations;Cardiology and Therapy;2020-05-25

3. One year follow-up of patients with reduced left ventricular ejection fraction (LVEF) on lipoprotein apheresis;Atherosclerosis Supplements;2019-12

4. Inhibidores de la PCSK9: una nueva mejora para la salud;Clínica e Investigación en Arteriosclerosis;2019-09

5. PCSK9 inhibitors: A new improvement for health;Clínica e Investigación en Arteriosclerosis (English Edition);2019-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3